A Phase 3 interventional study of mRNA-1273 and Placebo in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 100 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 2nd largest by enrollment, is one of 4 that started in 2020, is one of 10 in phase 3, and was the 3rd registered.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 14 · Phase 4 7
First in 2020; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30,415 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 499 across the 36 interventional studies. Of the 24 that completed or were terminated, 16 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
34 studies in COVID-19 by Moderna, Inc.: 3 open now, 6 under way, none of them phase 3. Of 28 finished, 11 (39%) have results posted.
Among the 34 studies in COVID-19 by Moderna, Inc., this one has the largest enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2020, is one of 6 in phase 3, and was the 2nd registered.
Moderna, Inc.’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, from their registry updates:
Among Moderna, Inc.’s 34 in COVID-19:
This tab as a report to print or save as PDF → With an account.
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
This is a 3-part Phase 3 study, with Part A (Blinded Phase), Part B (Open-label Observational Phase), and Part C (Booster Dose Phase). Participants in Part A are blinded to their treatment assignment, with participants receiving either mRNA-1273 vaccine or placebo. Part B of the study is designed to offer participants to be unblinded so that participants who received placebo in Part A can request 2 doses of open-label mRNA-1273 vaccine. Additionally, participants who choose to be unblinded and were only able to receive 1 dose of mRNA-1273 due to administrative reasons, can choose to receive the second dose of mRNA-1273 during Part B. In Part C, a booster dose will be provided for all eligible participants who choose to receive one.
Please access www.modernatx.com/cove-study for additional information, such as Study Overview, Participation, and Site Locations along with contact numbers for each location for the study.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 30,415 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A (Blinded): Participants will receive 1 intramuscular (IM) injection of 100 microgram (μg) mRNA-1273 on Day 1 and on Day 29. Part B (Open-label): Participants who receive mRNA-1273-matching placebo during Part A and choose to be unblinded by participating in Part B, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1 and Day 29. Participants who are only able to receive 1 dose of mRNA-1273 due to administrative reasons, will receive 1 IM injection of 100 μg mRNA-1273 on Day 1, if the participant chooses. Part C: Eligible participants in Part B who choose to receive booster dose of mRNA-1273, will receive 1 IM injection of 50 μg mRNA-1273 on Day 1.
Biological: mRNA-1273 · Biological: Placebo
Part A only: Participants will receive 1 IM injection of mRNA-1273-matching placebo on Day 1 and on Day 29, if the participant chooses.
Biological: Placebo
Sterile liquid for injection
0.9% sodium chloride (normal saline) injection
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.
Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First Dose
Solicited ARs (local and systemic) were collected in electronic diary (eDiary) within 7 days of dosing. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Severity grading for solicited ARs is based on modified Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials. Severity was graded 0-4; a lower score indicated lower severity and a higher score indicated greater severity. The Investigator determined if solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.
Time frame: up to Day 7 (7 days after first dose)
Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second Dose
Solicited ARs (local and systemic) were collected in eDiary within 7 days of dosing. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Severity grading for solicited ARs is based on modified Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials. Severity was graded 0-4; lower score indicated lower severity and a higher score indicated greater severity. The Investigator determined if solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section
Time frame: Day 29 to Day 35 (from second dose to 7 days after second dose)
Parts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to Discontinuation
An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Day 1 (after dosing) through end of study (up to Day 759)
Parts A and B: Number of Participants With Serious AEs (SAEs)
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Day 1 (after dosing) through end of study (up to Day 759)
Part A: Number of Participants With Unsolicited AEs up to 28 Days After Any Injection Dose
Unsolicited AE was any AE reported by the participant that was not specified as an AR or was specified as a solicited AR in the protocol but started outside the protocol-defined, post-injection period for reporting solicited ARs. Unsolicited AEs were collected for the 28 days after any injection. An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Up to 28 days after any dose
Parts A and B: Number of Participants With a First Occurrence of Severe COVID-19 Starting 14 Days After Second Dose
COVID-19 cases were defined as participants meeting clinical criteria based on symptoms for COVID-19 and reverse transcriptase polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 from samples collected within 72 hours of the participant reporting symptoms meeting the definition of COVID-19. An adjudication committee reviewed potential cases to determine if the criteria for COVID-19 were met. Clinical signs indicative of severe COVID-19 systemic illness included any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation (SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeter of mercury (mm Hg), or respiratory failure or acute respiratory distress syndrome (ARDS), evidence of shock, or significant acute renal, hepatic, or neurologic dysfunction, or admission to an intensive care unit or death.
Time frame: From Day 43 (14 days after second dose) up to approximately 8 months for Part A and from PDV/unblinding (at 4 months) to up to 8 months for Part B
Part A: Number of Participants With a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection Regardless of Symptomatology or Severity Starting 14 Days After Second Dose
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met. SARS-CoV-2 infection was defined by seroconversion due to infection measured by binding antibody (bAb) levels against SARS-CoV-2 nucleocapsid or by positive RT-PCR at predefined timepoints. Seroconversion was defined by the participant's serostatus at baseline.
Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Part A: Number of Participants With a Secondary Case Definition of COVID-19 Starting 14 Days After Second Dose
Secondary case definition of COVID-19 was defined as the presence of at least 1 of the following systemic symptoms: fever (temperature ≥38ºC), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches or body aches, headache, new loss of taste or smell, sore throat, nasal congestion or rhinorrhea, nausea or vomiting, or diarrhea and a positive nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) for SARS-CoV-2 by RT-PCR.
Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Parts A and B: Number of Participants Who Died Due to a Cause Directly Attributed to a Complication of COVID-19 Starting 14 Days After Second Dose
Time frame: From Day 43 (14 days after second dose) up to approximately 8 months for Part A and from PDV/unblinding (at 4 months) to up to 8 months for Part B
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After First Dose
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.
Time frame: From 14 days after first dose up to approximately 8 months
Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose Regardless of Evidence of Prior SARS-CoV-2 Infection
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.
Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Part A: Number of Participants With a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 Days After Second Dose
SARS-CoV-2 infection was defined by seroconversion due to infection measured by binding antibody (bAb) levels against SARS-CoV-2 nucleocapsid or by positive RT-PCR at predefined timepoints. Seroconversion was defined by the participant's serostatus at baseline.
Time frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
Part A: Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb)
GMT (50% inhibitory dose \[ID50\], 80% inhibitory dose \[ID80\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. 95% CI was based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.
Time frame: Day 1, Day 29, Day 57
Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. GMFR for ID50 and ID80 neutralizing antibodies against SARS-CoV-2 S-protein, as measured by pseudovirus neutralizing antibody is presented. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1
Time frame: Day 29, Day 57
Part A: Percentage of Participants With Seroresponse Against SARS-CoV-2
Seroresponse to pseudovirus neutralizing antibody ID50 titer at a participant level is defined as a change from below the LLOQ to equal or above the LLOQ, or at least a 3.3-fold rise if baseline is equal to or above the LLOQ. Seroresponse to pseudovirus neutralizing antibody ID80 titer at a participant level is defined as a change from below the LLOQ to equal or above the LLOQ, or at least a 2.3-fold rise if baseline is equal to or above the LLOQ. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.
Time frame: Day 29, Day 57
Part C: GMT of SARS-CoV-2 Specific nAb Measured by Pseudovirus (VAC62)
95% CI is calculated based on the t-distribution of the log-transformed values for GM value, then back transformed to the original scale for presentation.
Time frame: Pre-booster (Baseline), post-booster Day 29 and post-booster Day 181
Part C: Percentage of Participants With Seroresponse Against SARS-CoV-2 Measured by Pseudovirus (VAC62)
Pseudovirus neutralizing antibody (VAC62) from pre-booster is presented. Seroresponse at a participant level is defined as a change from below the LLOQ to \>= 4 x LLOQ, or at least a 4-fold rise if pre-booster is equal to or above the LLOQ.
Time frame: Post-booster Day 29 and post-booster Day 181
Part C: Geometric Mean Concentration (GMC) of SARS-CoV-2 Specific nAb After BD Compared to After Second Dose in Part A Measured by Pseudovirus (VAC62)
95% CI is calculated based on the t-distribution of the log-transformed values for GMC, then back transformed to the original scale for presentation.
Time frame: Part C BD Day 29 and Part A Day 57
Part C: Percentage of Participants With Seroresponse Against SARS-CoV-2 After BD Compared to After Second Dose in Part A
Pseudovirus neutralizing antibody (VAC62) are presented. Seroresponse at a participant level is defined as a change from below the LLOQ to equal or above 4 x LLOQ, or at least a4-fold rise if baseline (Pre- Dose 1) is equal to or above the LLOQ.
Time frame: Part C BD Day 29 and Part A Day 57
| Milestone | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 | Part C: mRNA-1273 Booster |
|---|---|---|---|---|---|---|
| Started | 15206 | 15209 | 0 | 0 | 0 | 0 |
| Received any study injection | 15166 | 15180 | 0 | 0 | 0 | 0 |
| Per-protocol (pp) set: | 14164 | 14287 | 0 | 0 | 0 | 0 |
| Per-protocol random subcohort for immunogenicity (pprsi) | 272 | 1185 | 0 | 0 | 0 | 0 |
| Solicited safety set | 15159 | 15179 | 0 | 0 | 0 | 0 |
| Safety set | 15162 | 15184 | 0 | 0 | 0 | 0 |
| Full analysis set | 15166 | 15180 | 0 | 0 | 0 | 0 |
| Completed | 14375 | 14661 | 0 | 0 | 0 | 0 |
| Not completed | 831 | 548 | 0 | 0 | 0 | 0 |
| Withdrew: Discontinued from study in part a | 831 | 548 | 0 | 0 | 0 | 0 |
| Milestone | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 | Part C: mRNA-1273 Booster |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 2513 | 12649 | 15184 | 0 |
| Safety set | 0 | 0 | 2513 | 12649 | 15184 | 0 |
| Pp set | 0 | 0 | 2104 | 12060 | 14287 | 0 |
| Participants who had pdv/unblinding) and had the option to receive booster dose in part c | 0 | 0 | 1725 | 12649 | 14661 | 0 |
| Completed | 0 | 0 | 149 | 10464 | 10171 | 0 |
| Not completed | 0 | 0 | 2364 | 2185 | 5013 | 0 |
| Withdrew: Other than specified | 0 | 0 | 788 | 0 | 523 | 0 |
| Withdrew: Discontinued from study in part b | 0 | 0 | 1576 | 2185 | 4490 | 0 |
| Milestone | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 | Part C: mRNA-1273 Booster |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 19609 |
| Pp set | 0 | 0 | 0 | 0 | 0 | 16368 |
| Pp immunogenicity subset (ppis) | 0 | 0 | 0 | 0 | 0 | 731 |
| Ppis-negative (neg) | 0 | 0 | 0 | 0 | 0 | 682 |
| Completed | 0 | 0 | 0 | 0 | 0 | 16691 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2918 |
| Withdrew: Discontinued from study in part c | 0 | 0 | 0 | 0 | 0 | 2918 |
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose | 744 | 55 |
Solicited ARs (local and systemic) were collected in electronic diary (eDiary) within 7 days of dosing. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Severity grading for solicited ARs is based on modified Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials. Severity was graded 0-4; a lower score indicated lower severity and a higher score indicated greater severity. The Investigator determined if solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Grade 1 | 5134 | 9329 |
| Grade 2 | 1782 | 3134 |
| Grade 3 | 363 | 849 |
| Grade 4 | 6 | 5 |
Solicited ARs (local and systemic) were collected in eDiary within 7 days of dosing. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Severity grading for solicited ARs is based on modified Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials. Severity was graded 0-4; lower score indicated lower severity and a higher score indicated greater severity. The Investigator determined if solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Grade 1 | 4346 | 4847 |
| Grade 2 | 1558 | 5800 |
| Grade 3 | 348 | 2895 |
| Grade 4 | 3 | 14 |
An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner (HCP). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 |
|---|---|---|---|---|---|
| MAAEs | 4561 | 3921 | 109 | 5513 | 5809 |
| AEs Leading to Discontinuation | 25 | 27 | 3 | 30 | 35 |
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 |
|---|---|---|---|---|---|
| Parts A and B: Number of Participants With Serious AEs (SAEs) | 308 | 292 | 15 | 536 | 516 |
Unsolicited AE was any AE reported by the participant that was not specified as an AR or was specified as a solicited AR in the protocol but started outside the protocol-defined, post-injection period for reporting solicited ARs. Unsolicited AEs were collected for the 28 days after any injection. An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Part A: Number of Participants With Unsolicited AEs up to 28 Days After Any Injection Dose | 4338 | 4752 |
COVID-19 cases were defined as participants meeting clinical criteria based on symptoms for COVID-19 and reverse transcriptase polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 from samples collected within 72 hours of the participant reporting symptoms meeting the definition of COVID-19. An adjudication committee reviewed potential cases to determine if the criteria for COVID-19 were met. Clinical signs indicative of severe COVID-19 systemic illness included any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation (SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeter of mercury (mm Hg), or respiratory failure or acute respiratory distress syndrome (ARDS), evidence of shock, or significant acute renal, hepatic, or neurologic dysfunction, or admission to an intensive care unit or death.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 |
|---|---|---|---|---|---|
| Parts A and B: Number of Participants With a First Occurrence of Severe COVID-19 Starting 14 Days After Second Dose | 106 | 2 | 1 | 8 | 1 |
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met. SARS-CoV-2 infection was defined by seroconversion due to infection measured by binding antibody (bAb) levels against SARS-CoV-2 nucleocapsid or by positive RT-PCR at predefined timepoints. Seroconversion was defined by the participant's serostatus at baseline.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Part A: Number of Participants With a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection Regardless of Symptomatology or Severity Starting 14 Days After Second Dose | 1339 | 280 |
Secondary case definition of COVID-19 was defined as the presence of at least 1 of the following systemic symptoms: fever (temperature ≥38ºC), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches or body aches, headache, new loss of taste or smell, sore throat, nasal congestion or rhinorrhea, nausea or vomiting, or diarrhea and a positive nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) for SARS-CoV-2 by RT-PCR.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Part A: Number of Participants With a Secondary Case Definition of COVID-19 Starting 14 Days After Second Dose | 807 | 58 |
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 |
|---|---|---|---|---|---|
| Parts A and B: Number of Participants Who Died Due to a Cause Directly Attributed to a Complication of COVID-19 Starting 14 Days After Second Dose | 3 | 0 | 0 | 0 | 0 |
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After First Dose | 769 | 56 |
COVID-19 cases were defined as participants meeting clinical criteria based both on symptoms for COVID-19 and on RT-PCR detection of SARS-CoV-2 from samples collected within 72 hours of the study participant reporting symptoms that met the definition of COVID-19. An adjudication committee was assembled for the purpose of reviewing potential cases to determine if the criteria for COVID-19 were met.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose Regardless of Evidence of Prior SARS-CoV-2 Infection | 754 | 58 |
SARS-CoV-2 infection was defined by seroconversion due to infection measured by binding antibody (bAb) levels against SARS-CoV-2 nucleocapsid or by positive RT-PCR at predefined timepoints. Seroconversion was defined by the participant's serostatus at baseline.
| Participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Part A: Number of Participants With a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 Days After Second Dose | 498 | 214 |
GMT (50% inhibitory dose \[ID50\], 80% inhibitory dose \[ID80\]) of nAb against SARS-CoV-2 pseudotyped viruses as measured by pseudovirus nAb assay is reported. 95% CI was based on the t-distribution of log-transformed values for GM titer, then back transformed to original scale for presentation. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.
| Titer | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Baseline SARS-CoV-2 Negative, ID50, Day 1 | NA (NA to NA) | 9.624 (9.35 to 9.90) |
| Baseline SARS-CoV-2 Negative', ID50, Day 29 | 9.515 (9.00 to 10.06) | 54.866 (50.98 to 59.04) |
| Baseline SARS-CoV-2 Negative', ID50, Day 57 | 9.903 (8.99 to 10.90) | 1081.124 (1019.80 to 1146.14) |
| Baseline SARS-CoV-2 Negative', ID80, Day 1 | NA (NA to NA) | 7.332 (7.18 to 7.49) |
| Baseline SARS-CoV-2 Negative', ID80, Day 29 | 7.279 (7.03 to 7.54) | 19.684 (18.55 to 20.89) |
| Baseline SARS-CoV-2 Negative', ID80, Day 57 | 7.522 (7.00 to 8.09) | 334.867 (317.84 to 352.81) |
| Baseline SARS-CoV-2 Positive, ID50, Day 1 | 82.519 (59.40 to 114.64) | 68.117 (49.88 to 93.02) |
| Baseline SARS-CoV-2 Positive, ID50, Day 29 | 52.728 (39.45 to 70.48) | 1478.910 (1069.60 to 2044.86) |
| Baseline SARS-CoV-2 Positive, ID50, Day 57 | 47.708 (35.41 to 64.28) | 3145.904 (2539.80 to 3896.66) |
| Baseline SARS-CoV-2 Positive, ID80, Day 1 | 29.580 (22.39 to 39.09) | 24.996 (19.12 to 32.68) |
| Baseline SARS-CoV-2 Positive, ID80, Day 29 | 20.994 (16.42 to 26.84) | 518.388 (380.39 to 706.44) |
| Baseline SARS-CoV-2 Positive, ID80, Day 57 | 19.228 (15.03 to 24.60) | 1099.847 (903.83 to 1338.37) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. GMFR for ID50 and ID80 neutralizing antibodies against SARS-CoV-2 S-protein, as measured by pseudovirus neutralizing antibody is presented. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1
| Ratio | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Baseline SARS-CoV-2 Negative, ID50 Day 29 | 1.03 (0.97 to 1.09) | 5.69 (5.29 to 6.12) |
| Baseline SARS-CoV-2 Negative, ID50 Day 57 | 1.07 (0.97 to 1.18) | 112.30 (105.42 to 119.62) |
| Baseline SARS-CoV-2, Negative, ID80 Day 29 | 1.02 (0.98 to 1.05) | 2.68 (2.53 to 2.84) |
| Baseline SARS-CoV-2 Negative, ID80 Day 57 | 1.05 (0.98 to 1.13) | 45.62 (43.21 to 48.17) |
| Baseline SARS-CoV-2, Positive, ID50 Day 29 | 0.64 (0.56 to 0.73) | 21.71 (16.08 to 29.32) |
| Baseline SARS-CoV-2 Positive, ID50 Day 57 | 0.59 (0.50 to 0.69) | 46.18 (34.10 to 62.55) |
| Baseline SARS-CoV-2 Positive, ID80 Day 29 | 0.71 (0.64 to 0.79) | 20.74 (15.30 to 28.10) |
| Baseline SARS-CoV-2 Positive, ID80 Day 57 | 0.66 (0.57 to 0.75) | 44.00 (33.99 to 56.97) |
Seroresponse to pseudovirus neutralizing antibody ID50 titer at a participant level is defined as a change from below the LLOQ to equal or above the LLOQ, or at least a 3.3-fold rise if baseline is equal to or above the LLOQ. Seroresponse to pseudovirus neutralizing antibody ID80 titer at a participant level is defined as a change from below the LLOQ to equal or above the LLOQ, or at least a 2.3-fold rise if baseline is equal to or above the LLOQ. Baseline SARS-CoV-2 Status: Positive if there is immunologic or virologic evidence of prior COVID-19, defined as positive RT-PCR test or positive Elecsys result at Day 1. Negative is defined as negative RT-PCR test and negative Elecsys result at Day 1.
| percentage of participants | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 |
|---|---|---|
| Baseline SARS-CoV-2 Negative, ID50, Day 29 | 0.7 (0.0 to 3.9) | 81.4 (78.9 to 83.7) |
| Baseline SARS-CoV-2 Negative, ID50, Day 57 | 1.4 (0.2 to 5.0) | 98.9 (98.0 to 99.4) |
| Baseline SARS-CoV-2 Negative, ID80, Day 29 | 0.7 (0.0 to 3.9) | 63.0 (60.0 to 65.9) |
| Baseline SARS-CoV-2 Negative, ID80, Day 57 | 1.4 (0.2 to 5.0) | 98.9 (98.0 to 99.4) |
| Baseline SARS-CoV-2 Positive, ID50, Day 29 | 0.8 (0.0 to 4.3) | 87.7 (80.8 to 92.8) |
| Baseline SARS-CoV-2 Positive, ID50, Day 57 | 1.6 (0.2 to 5.5) | 94.6 (89.2 to 97.8) |
| Baseline SARS-CoV-2 Positive, ID80, Day 29 | 3.1 (0.9 to 7.8) | 90.0 (83.5 to 94.6) |
| Baseline SARS-CoV-2 Positive, ID80, Day 57 | 2.3 (0.5 to 6.6) | 96.2 (91.3 to 98.7) |
95% CI is calculated based on the t-distribution of the log-transformed values for GM value, then back transformed to the original scale for presentation.
| Titer | Part C (Booster): mRNA-1273 Booster |
|---|---|
| Pre-booster (Baseline) | 163.848 (147.977 to 181.421) |
| BD Day 29 | 8122.189 (7603.021 to 8676.808) |
| BD Day 181 | 2951.123 (2701.648 to 3223.636) |
Pseudovirus neutralizing antibody (VAC62) from pre-booster is presented. Seroresponse at a participant level is defined as a change from below the LLOQ to \>= 4 x LLOQ, or at least a 4-fold rise if pre-booster is equal to or above the LLOQ.
| percentage of participants | Part C (Booster): mRNA-1273 Booster |
|---|---|
| BD Day 29 | 94.5 (92.5 to 96.1) |
| BD Day 181 | 89.2 (86.4 to 91.6) |
95% CI is calculated based on the t-distribution of the log-transformed values for GMC, then back transformed to the original scale for presentation.
| arbitrary units (AU)/milliliters (mL) | Part C (Booster): mRNA-1273 Booster | Part A mRNA-1273 |
|---|---|---|
| Part C BD Day 29 | 7739.680 (7240.926 to 8272.789) | — |
| Part A Day 57 | — | 1111.274 (1041.684 to 1185.513) |
Pseudovirus neutralizing antibody (VAC62) are presented. Seroresponse at a participant level is defined as a change from below the LLOQ to equal or above 4 x LLOQ, or at least a4-fold rise if baseline (Pre- Dose 1) is equal to or above the LLOQ.
| percentage of participants | Part C (Booster): mRNA-1273 Booster | Part A mRNA-1273 |
|---|---|---|
| Part C BD Day 29 | 100 (99.4 to 100) | — |
| Part A Day 57 | — | 98.8 (97.7 to 99.5) |
Collected over up to Day 759 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A (Blinded): Placebo | 18/15,206 (0.1%) | 308/15,162 (2%) | 2,783/15,162 (18.4%) |
| Part A (Blinded): mRNA-1273 | 16/15,209 (0.1%) | 292/15,184 (1.9%) | 2,247/15,184 (14.8%) |
| Part B (Open-label): Placebo | 2/2,513 (0.1%) | 15/2,513 (0.6%) | 42/2,513 (1.7%) |
| Part B (Open-label): Placebo/mRNA-1273 | 23/12,649 (0.2%) | 536/12,649 (4.2%) | 1,739/12,649 (13.7%) |
| Part B (Open-label): mRNA-1273 | 35/15,184 (0.2%) | 516/15,184 (3.4%) | 1,404/15,184 (9.2%) |
| Part C: mRNA-1273 Booster | 52/19,609 (0.3%) | 755/19,609 (3.9%) | 8,277/19,609 (42.2%) |
| Event | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 | Part C: mRNA-1273 Booster |
|---|---|---|---|---|---|---|
| Cardiac disordersEar and labyrinth disorders | 45/15162 | 44/15184 | 2/2513 | 85/12649 | 81/15184 | 142/19609 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 19/15162 | 12/15184 | 1/2513 | 30/12649 | 21/15184 | 21/19609 |
| COVID-19Infections and infestations | 33/15162 | 1/15184 | 2/2513 | 10/12649 | 6/15184 | 8/19609 |
| PneumoniaInfections and infestations | 11/15162 | 9/15184 | 1/2513 | 25/12649 | 13/15184 | 19/19609 |
| Atrial fibrillationEar and labyrinth disorders | 11/15162 | 7/15184 | 0/2513 | 11/12649 | 13/15184 | 27/19609 |
| SepsisInfections and infestations | 4/15162 | 4/15184 | 0/2513 | 16/12649 | 9/15184 | 7/19609 |
| Coronary artery diseaseEar and labyrinth disorders | 3/15162 | 5/15184 | 0/2513 | 15/12649 | 12/15184 | 18/19609 |
| Acute myocardial infarctionEar and labyrinth disorders | 6/15162 | 4/15184 | 1/2513 | 10/12649 | 11/15184 | 21/19609 |
| AppendicitisInfections and infestations | 5/15162 | 4/15184 | 0/2513 | 13/12649 | 7/15184 | 13/19609 |
| DiverticulitisInfections and infestations | 4/15162 | 2/15184 | 0/2513 | 12/12649 | 4/15184 | 6/19609 |
| Event | Part A (Blinded): Placebo | Part A (Blinded): mRNA-1273 | Part B (Open-label): Placebo | Part B (Open-label): Placebo/mRNA-1273 | Part B (Open-label): mRNA-1273 | Part C: mRNA-1273 Booster |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 947/15162 | 92/15184 | 21/2513 | 489/12649 | 650/15184 | 4885/19609 |
| Injection site painGeneral disorders | 165/15162 | 327/15184 | 0/2513 | 559/12649 | 45/15184 | 2764/19609 |
| FatigueGeneral disorders | 954/15162 | 1078/15184 | 6/2513 | 343/12649 | 141/15184 | 1515/19609 |
| HeadacheNervous system disorders | 1046/15162 | 1087/15184 | 4/2513 | 384/12649 | 200/15184 | 1150/19609 |
| Upper respiratory tract infectionInfections and infestations | 361/15162 | 305/15184 | 18/2513 | 441/12649 | 491/15184 | 1017/19609 |
All randomized participants who received at least 1 dose of treatment.
| Age, Continuous(years) | Placebo | mRNA-1273 | Total |
|---|---|---|---|
| Mean | 51.3 ± 15.60 | 51.4 ± 15.50 | 51.4 ± 15.55 |
| Sex: Female, Male(Participants) | Placebo | mRNA-1273 | Total |
|---|---|---|---|
| Female | 7109 | 7263 | 14372 |
| Male | 8057 | 7917 | 15974 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | mRNA-1273 | Total |
|---|---|---|---|
| Hispanic or Latino | 3109 | 3121 | 6230 |
| Not Hispanic or Latino | 11921 | 11917 | 23838 |
| Unknown or Not Reported | 136 | 142 | 278 |
| Race/Ethnicity, Customized(Participants) | Placebo | mRNA-1273 | Total |
|---|---|---|---|
| Race — White | 12001 | 12031 | 24032 |
| Race — Black or African American | 1531 | 1567 | 3098 |
| Race — Asian | 739 | 656 | 1395 |
| Race — American Indian or Alaska Native | 121 | 113 | 234 |
| Race — Native Hawaiian or other Pacific Islander | 32 | 36 | 68 |
| Race — Multiracial | 319 | 319 | 638 |
| Race — Other | 294 | 299 | 593 |
| Race — Not Reported | 74 | 97 | 171 |
| Race — Unknown | 55 | 62 | 117 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Dec 2022, 29 months.
Results were first posted in Mar 2024, 1 year 2 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 29 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273